Horizon Discovery Group plc announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals Inc. A clinical stage biopharmaceutical company based in South San Francisco, California, NGM is focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. Horizon’s proprietary GS knockout CHO K1 cell line and protocols facilitate the development of stable cell lines for the expression of antibodies and other recombinant proteins. The Company also licenses a CHO expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations.